Colgate-Palmolive Company vs Neurocrine Biosciences Inc — how do they compare? Colgate-Palmolive Company trades at $90.95 (market cap $72.84B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.30B). The key difference: Colgate-Palmolive Company is far larger — about 4.2× Neurocrine Biosciences Inc's market cap, and Colgate-Palmolive Company pays a 2.33% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CL | NBIX | |
|---|---|---|
Market Cap | $72.84B | $17.30B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $180.55 |
52-Week Low | $74.98 | $123.10 |
Enterprise Value | $79.48B | $16.39B |
Dividend Yield | 2.33% | — |
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.21, up 1.05% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 60.06% gross margins and 822.05% ROE, though valuation metrics appear elevated with a P/E of 36.13. Recent dividend declarations and positive analyst coverage (42% buy rating) support the defensive stock's appeal amid market rotation into stable cash flow names.
Outlook remains positive with a $97 consensus price target representing 4% upside, though premium valuation and North American segment softness present headwinds. The company's 64-year dividend growth streak and global diversification provide stability, while inflation pressures and competitive threats require monitoring for sustained outperformance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →